Table 3. Clinical Variables Associated... | American Society of Hematology

Table 3.

Clinical Variables Associated With EPOCH Resistance

Variables	No. of Patients (%)
	No.	Resistant^3-150	P₂
LDH
Normal	32	4 (13)
Elevated	43	15 (35)	.027
PS
0-1	31	2 (6)
2-4	44	17 (39)	.002
Stage
I/II	11	4 (36)
III/IV	64	15 (23)	.46
Extranodal sites
0-1	58	16 (28)
≥2	17	3 (18)	.53
Age^3-151	—	—	.034
Mass >10 cm
−	58	10 (17)
+	17	9 (53)	.009
Refractory disease^3-152
−	51	8 (16)
+	24	11 (46)	.005
Histology
Low-grade	15	4 (27)
Progressed low-grade	23	2 (9)	.07
Intermediate-grade	37	13 (35)

Variables	No. of Patients (%)
	No.	Resistant^3-150	P₂
LDH
Normal	32	4 (13)
Elevated	43	15 (35)	.027
PS
0-1	31	2 (6)
2-4	44	17 (39)	.002
Stage
I/II	11	4 (36)
III/IV	64	15 (23)	.46
Extranodal sites
0-1	58	16 (28)
≥2	17	3 (18)	.53
Age^3-151	—	—	.034
Mass >10 cm
−	58	10 (17)
+	17	9 (53)	.009
Refractory disease^3-152
−	51	8 (16)
+	24	11 (46)	.005
Histology
Low-grade	15	4 (27)
Progressed low-grade	23	2 (9)	.07
Intermediate-grade	37	13 (35)

Statistically significant P values are shown in boldface.

Abbreviation: PS, performance status.

No response.

Mean age in years: nonresponders, 39, versus responders, 55.

No response to prior regimen.